论文部分内容阅读
本文从病理组织学和临床治疗两万面探讨SRCA作为抗癌药物敏感试验可行性.96例病理组织学研究表明,4至5天SRCA移值物重量的增加与宿主细胞浸润无明显相关性,但移植物中瘤细胞保存仍不太理想,未观察到明显分裂增殖现象,约45%的病例可观察到药物作用反应.42例中晚期病人临床观察,治疗反应(CR+PR)有效率为78%.作者认为,移值后在药物作用基础上产生的不同程度水肿可能是导致移植物大小改变的重要因素之一.4天SRCA作为一种选择抗癌药物的预测方法,具有一定的客观实用性.
This article discussed the feasibility of SRCA as an anti-cancer drug sensitivity test from 20,000 histopathological and clinical treatments. 96 histopathological studies have shown that there is no significant correlation between the weight gain of SRCA shifts and host cell infiltration at 4 to 5 days. However, the preservation of tumor cells in the grafts is still not ideal, no obvious proliferation and proliferation are observed, about 45% of the cases can be observed drug response. 42 patients with intermediate and late patients clinical observation, the effective rate of treatment response (CR+PR) 78%. The authors believe that different degrees of edema on the basis of drug effects after the transfer may be one of the important factors leading to changes in graft size. 4 days SRCA as a method of anti-cancer drug selection, has a certain degree of objective Practicality.